New eyedrop shows promise for pink eye in small trial

NCT ID NCT05356793

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a new anti-infective eyedrop called SCH1 in 30 adults with acute infectious conjunctivitis (pink eye). Participants received either the active eyedrop or a placebo. The goal was to see if the drug could completely clear redness and discharge. The trial is complete, and results are being analyzed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SCH-1 eyedrop (novel anti-infective)

What this could lead to

If successful, this could provide a new treatment option for pink eye, potentially reducing symptoms faster than current care.

What could go wrong

This is a small, early-phase trial with only 30 participants. The results may not apply to everyone, and the drug may not prove more effective than a placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE INFECTIOUS CONJUNCTIVITIS (DISORDER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute contagious conjunctivitis conjunctivitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Jacqueline Dauhajre, MD

    Jackson Heights, New York, 11372, United States